Dr. Infante on the Next Step in Melanoma Research

Video

Dr. Jeffrey Infante from Sarah Cannon Research Institute on the Next Step in Melanoma Research

Jeffrey Infante, MD, director of drug development at the Sarah Cannon Research Institute on the next step in melanoma research.

Related Videos
Josep Maria Piulats Rodriguez, MD, PhD
Samer A. Srour, MB ChB, MS
William B. Pearse, MD
Núria Agustí Garcia, MD
Mikkael A. Sekeres, MD, MS
Benjamin Levy, MD
Alessandra Ferrajoli, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
Sangeeta Goswami, MD, PhD, of The University of Texas MD Anderson Cancer Center
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Related Content
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024
Article
Jeffrey S. Weber, MD, PhD

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

November 6th 2023
Podcast
James Isaacs, MD, of Cleveland Clinic

Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

April 10th 2024
Article
Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

March 6th 2023
Podcast
Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center

Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC

April 8th 2024
Article
C. Michel Zwaan, MD, PhD, of Erasmus MC Rotterdam and the Princess Máxima Center

Revumenib Demonstrates Activity in Pediatric Patients With KMT2A+ Acute Leukemia

April 4th 2024
Article